The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment

NCT ID: NCT05298657

Last Updated: 2022-07-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-01

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

According the World Health Organization (WHO), infertility is a disease of the male or female reproductive system defined by the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. In-vitro-fertilization (IVF) is considered to be a successful tool to overcome infertility. However, the current methods used to assess the ovarian reserve and to develop an optimal individualized controlled ovarian hyperstimulation (COH) protocol have shown some limitations. Growing evidence indicates that altered renal renin-angiotensin system (RAS) and/or melatonin are linked to infertility. Aims and Objectives: The current 2 years duration study aims first to investigate the demographic and clinical profiles of patients undergoing IVF in the UAE. In the second phase of the study, we hypothesis that an altered angiotensin-melatonin axis may be considered as an unfavorable prognosis factor in poor and hyper responders undergoing IVF treatment. This hypothesis will be assessed using an observational, longitudinal, prospective clinical study to determine whether the urinary angiotensinogen and/or melatonin deficiency might be present in poor and hyper responders undergoing IVF treatment. Thus, negatively impacting the clinical pregnancy rate. Methodology: various patient's data will be collected using a questionnaire and the levels of angiotensinogen and melatonin in patient's urine will be measured using ELISA test prior to, during and after the IVF treatment. To determine whether the angiotensinogen-melatonin axis disruption affects the IVF treatment outcome, we will analyze the following parameters: the AMH, Antral Follicular Count (AFC), day 2-4 FSH levels, the stimulation cycle in regards to number of stimulation days and amount of gonadotropins used for stimulation, number of oocytes retrieved and number of mature oocytes, quality and embryo's ploidy, number of available euploid embryos and the clinical pregnancy rate after frozen embryo transfer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Infertility affects approximately 1 in every 4 couples and the WHO (World Health Organization) has defined infertility as a "disease" (World Health Organization (WHO). International Classification of Diseases, 11th Revision (ICD-11) Geneva: WHO 2018.). Rates of infertility are expected to increase in the future as many couples tend to postpone family planning due to various reasons (Mills et al., 2011). Assisted Reproductive Techniques (ART), with In-vitro-fertilization (IVF) being a part of the treatment options, are a successful tool to overcome infertility (Franasiak \& Scott, 2014). However, more research to thwart the global burden of infertility is required. This is possible if the underlying causes of infertility can be identified, and personalized therapy implemented (Sun et al., 2019).

Poor and hyper responders are a diverse group of IVF patients, with specific needs. Their management can help in increasing the clinical pregnancy rates. Identifying and understanding how the endocrine variants are linked to the success of IVF responsiveness may lead to a better treatment strategy aimed at achieving successful live births.

Growing evidence indicates that altered renal renin-angiotensin system (RAS) and melatonin are linked to infertility, PCOS and endometriosis.

According to the literature, hyperandrogenemia in an experimental rat model of PCOS has been associated with an upregulation of the intrarenal RAS (Torres Fernandez et al. 2019). When compared to the eutopic endometrium in the proliferative phase, patients with endometriotic cysts had a significant increase in the expression of angiotensin type AT1 and AT2 receptors. This suggests that RAS may be involved in the pathophysiology of endometriosis (Nakao et al. 2017; Nakajima et al. 2018). In addition, alterations in the expression of Angiotensin-converting enzyme, ACE-1, ACE-2, and ACE-3 might be one of the most important mechanisms underlying both female and male infertility (Chen, Bi, Su, Chappell, \& Rose, 2016; Pan, Zhan, Le, Zheng, \& Jin, 2013).

On the other hand, the levels of melatonin, a powerful antioxidant and an effective free radical scavenger that protects ovarian follicles during follicular maturation are increasing in preovulatory follicular fluid and seem to have an important role in ovulation (Tamura et al., 2012). Similarly, melatonin requirements appear to increase during pregnancy (Voiculescu, Zygouropoulos, Zahiu, \& Zagrean, 2014). Melatonin levels are found to be lower in patients with PCOS (Mojaverrostami et al. 2019). And several studies suggest a potential link between melatonin and endometriosis (Mosher et al. 2019; Anderson 2019), leading to the use of melatonin as an adjuvant in the treatment of endometriosis (Mosher et al. 2019; Yesildaglar et al. 2016).

Clinical hypothesis:

This observational, longitudinal, prospective clinical study will investigate the IVF population demographic and clinical profile in the UAE. It will also test the hypothesis whether an altered angiotensin-melatonin axis may be considered an unfavorable prognosis factor in poor responders with or without endometriosis and hyper (PCOS) responders undergoing IVF treatment. Thus, negatively impacting the clinical pregnancy rate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Poor Response to Ovulation Induction PCOS Endometriosis Infertility, Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Poor IVF Treatment Responders

No interventions assigned to this group

Hyper IVF Treatment Responders

No interventions assigned to this group

Normal responders/ Control group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

depending on the ART Fertility Clinic patients, we are intending to include:

1. Women diagnosed with infertility (when pregnancy is not achieved after 1 year of having regular sexual intercourse without birth control for those under 35 years of age or if pregnancy is not achieved after 6 months of trying to conceive naturally for those older than 35 years of age). Further on, women with proven tubal factor infertility or couples with infertility as a result of a male factor, without the previously mentioned time of not achieving a pregnancy.
2. Women undergoing or in the way to undergo IVF and classified as poor responders according to the four groups of the POSEIDON criteria (Conforti et al., 2019), including patients with a previous oral contraceptive intake.
3. Women diagnosed with PCOS based on the Rotterdam criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004.
4. Women diagnosed with endometriosis confirmed by Laparoscopy or visible endometrioma without being diagnosed by laparoscopy (If possible to be enrolled in the research).
5. Women planned to undergo IVF treatment and categorized as expected normal responders) (Ozkan, 2019).
6. Patients under thyroid medication.

Exclusion Criteria

1. Presence or history of endocrine abnormalities (at the exception of patients who are under thyroid medication).
2. Abnormal outcome of blood biochemistry or hematology.
3. Obese patients with BMI \> 40.
4. Couples for whom the male partner has to undergo surgical sperm retrieval.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ART Fertility Clinics LLC

OTHER

Sponsor Role collaborator

Fatima College of Health Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rym Ghimouz

Assistant Professor of Biology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rym Ghimouz, PhD

Role: PRINCIPAL_INVESTIGATOR

Fatima College of Health Sciences

Barbara Lawrenz, PhD

Role: PRINCIPAL_INVESTIGATOR

ART Fertility Clinics

Luciana Campos, PhD

Role: PRINCIPAL_INVESTIGATOR

Universidade Anhembi Morumbi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ART Fertility Clinic

Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Arab Emirates

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rym Ghimouz, PhD

Role: CONTACT

+971551156892

Barbara Lawrenz, PhD

Role: CONTACT

+971526500757

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Barbara Lawrenz, PhD

Role: primary

+971526500757

References

Explore related publications, articles, or registry entries linked to this study.

Anderson G. Endometriosis Pathoetiology and Pathophysiology: Roles of Vitamin A, Estrogen, Immunity, Adipocytes, Gut Microbiome and Melatonergic Pathway on Mitochondria Regulation. Biomol Concepts. 2019 Jul 19;10(1):133-149. doi: 10.1515/bmc-2019-0017.

Reference Type BACKGROUND
PMID: 31339848 (View on PubMed)

Barbakadze L, Kristesashvili J, Khonelidze N, Tsagareishvili G. The correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women. Int J Fertil Steril. 2015 Jan-Mar;8(4):393-8. doi: 10.22074/ijfs.2015.4179. Epub 2015 Feb 7.

Reference Type BACKGROUND
PMID: 25780521 (View on PubMed)

Chen K, Bi J, Su Y, Chappell MC, Rose JC. Sex-Specific Changes in Renal Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Gene Expression and Enzyme Activity at Birth and Over the First Year of Life. Reprod Sci. 2016 Feb;23(2):200-10. doi: 10.1177/1933719115597760. Epub 2015 Aug 4.

Reference Type BACKGROUND
PMID: 26243544 (View on PubMed)

Conforti A, Esteves SC, Cimadomo D, Vaiarelli A, Di Rella F, Ubaldi FM, Zullo F, De Placido G, Alviggi C. Management of Women With an Unexpected Low Ovarian Response to Gonadotropin. Front Endocrinol (Lausanne). 2019 Jun 27;10:387. doi: 10.3389/fendo.2019.00387. eCollection 2019.

Reference Type BACKGROUND
PMID: 31316461 (View on PubMed)

Franasiak JM, Scott RT Jr. Embryonic aneuploidy: overcoming molecular genetics challenges improves outcomes and changes practice patterns. Trends Mol Med. 2014 Sep;20(9):499-508. doi: 10.1016/j.molmed.2014.06.006. Epub 2014 Aug 8.

Reference Type BACKGROUND
PMID: 25113799 (View on PubMed)

Irani M, Robles A, Gunnala V, Reichman D, Rosenwaks Z. Optimal parameters for determining the LH surge in natural cycle frozen-thawed embryo transfers. J Ovarian Res. 2017 Oct 16;10(1):70. doi: 10.1186/s13048-017-0367-7.

Reference Type BACKGROUND
PMID: 29037231 (View on PubMed)

Kuwayama M. Highly efficient vitrification for cryopreservation of human oocytes and embryos: the Cryotop method. Theriogenology. 2007 Jan 1;67(1):73-80. doi: 10.1016/j.theriogenology.2006.09.014. Epub 2006 Oct 20.

Reference Type BACKGROUND
PMID: 17055564 (View on PubMed)

La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014 Jan-Feb;20(1):124-40. doi: 10.1093/humupd/dmt037. Epub 2013 Sep 29.

Reference Type BACKGROUND
PMID: 24077980 (View on PubMed)

Levi-Setti PE, Zerbetto I, Baggiani A, Zannoni E, Sacchi L, Smeraldi A, Morenghi E, De Cesare R, Drovanti A, Santi D. An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patients Following the POSEIDON Criteria. Front Endocrinol (Lausanne). 2019 May 8;10:282. doi: 10.3389/fendo.2019.00282. eCollection 2019.

Reference Type BACKGROUND
PMID: 31139146 (View on PubMed)

Mills M, Rindfuss RR, McDonald P, te Velde E; ESHRE Reproduction and Society Task Force. Why do people postpone parenthood? Reasons and social policy incentives. Hum Reprod Update. 2011 Nov-Dec;17(6):848-60. doi: 10.1093/humupd/dmr026. Epub 2011 Jun 7.

Reference Type BACKGROUND
PMID: 21652599 (View on PubMed)

Mojaverrostami S, Asghari N, Khamisabadi M, Heidari Khoei H. The role of melatonin in polycystic ovary syndrome: A review. Int J Reprod Biomed. 2019 Dec 30;17(12):865-882. doi: 10.18502/ijrm.v17i12.5789. eCollection 2019 Dec.

Reference Type BACKGROUND
PMID: 31970309 (View on PubMed)

Mosher AA, Tsoulis MW, Lim J, Tan C, Agarwal SK, Leyland NA, Foster WG. Melatonin activity and receptor expression in endometrial tissue and endometriosis. Hum Reprod. 2019 Jul 8;34(7):1215-1224. doi: 10.1093/humrep/dez082.

Reference Type BACKGROUND
PMID: 31211323 (View on PubMed)

Nakajima T, Chishima F, Nakao T, Hayashi C, Kasuga A, Shinya K, Nakayama T, Azuma H, Ichikawa G, Komatsu A, Yamamoto T, Kawana K. The Expression of MAS1, an Angiotensin (1-7) Receptor, in the Eutopic Proliferative Endometria of Endometriosis Patients. Gynecol Obstet Invest. 2018;83(6):600-607. doi: 10.1159/000490561. Epub 2018 Jul 6.

Reference Type BACKGROUND
PMID: 29982252 (View on PubMed)

Nakao T, Chishima F, Sugitani M, Tsujimura R, Hayashi C, Yamamoto T. Expression of Angiotensin II Types 1 and 2 Receptors in Endometriotic Lesions. Gynecol Obstet Invest. 2017;82(3):294-302. doi: 10.1159/000447591. Epub 2016 Jul 7.

Reference Type BACKGROUND
PMID: 27384958 (View on PubMed)

Pan PP, Zhan QT, Le F, Zheng YM, Jin F. Angiotensin-converting enzymes play a dominant role in fertility. Int J Mol Sci. 2013 Oct 21;14(10):21071-86. doi: 10.3390/ijms141021071.

Reference Type BACKGROUND
PMID: 24152441 (View on PubMed)

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25. doi: 10.1016/j.fertnstert.2003.10.004.

Reference Type BACKGROUND
PMID: 14711538 (View on PubMed)

Rubio C, Rodrigo L, Garcia-Pascual C, Peinado V, Campos-Galindo I, Garcia-Herrero S, Simon C. Clinical application of embryo aneuploidy testing by next-generation sequencing. Biol Reprod. 2019 Dec 24;101(6):1083-1090. doi: 10.1093/biolre/ioz019.

Reference Type BACKGROUND
PMID: 30721942 (View on PubMed)

Steiner AZ, Pritchard D, Stanczyk FZ, Kesner JS, Meadows JW, Herring AH, Baird DD. Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA. 2017 Oct 10;318(14):1367-1376. doi: 10.1001/jama.2017.14588.

Reference Type BACKGROUND
PMID: 29049585 (View on PubMed)

Sun H, Gong TT, Jiang YT, Zhang S, Zhao YH, Wu QJ. Global, regional, and national prevalence and disability-adjusted life-years for infertility in 195 countries and territories, 1990-2017: results from a global burden of disease study, 2017. Aging (Albany NY). 2019 Dec 2;11(23):10952-10991. doi: 10.18632/aging.102497. Epub 2019 Dec 2.

Reference Type BACKGROUND
PMID: 31790362 (View on PubMed)

Tamura H, Takasaki A, Taketani T, Tanabe M, Kizuka F, Lee L, Tamura I, Maekawa R, Aasada H, Yamagata Y, Sugino N. The role of melatonin as an antioxidant in the follicle. J Ovarian Res. 2012 Jan 26;5:5. doi: 10.1186/1757-2215-5-5.

Reference Type BACKGROUND
PMID: 22277103 (View on PubMed)

Torres Fernandez ED, Huffman AM, Syed M, Romero DG, Yanes Cardozo LL. Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS. Endocrinology. 2019 Dec 1;160(12):2787-2799. doi: 10.1210/en.2019-00450.

Reference Type BACKGROUND
PMID: 31593246 (View on PubMed)

Voiculescu SE, Zygouropoulos N, Zahiu CD, Zagrean AM. Role of melatonin in embryo fetal development. J Med Life. 2014 Oct-Dec;7(4):488-92.

Reference Type BACKGROUND
PMID: 25713608 (View on PubMed)

Williams T, Mortada R, Porter S. Diagnosis and Treatment of Polycystic Ovary Syndrome. Am Fam Physician. 2016 Jul 15;94(2):106-13.

Reference Type BACKGROUND
PMID: 27419327 (View on PubMed)

Yesildaglar N, Yildirim G, Yildirim OK, Attar R, Ozkan F, Akkaya H, Yilmaz B. The effects of melatonin on endometriotic lesions induced by implanting human endometriotic cells in the first SCID-mouse endometriosis-model developed in Turkey. Clin Exp Obstet Gynecol. 2016;43(1):25-30.

Reference Type BACKGROUND
PMID: 27048013 (View on PubMed)

Zegers-Hochschild F, Nygren KG, Adamson GD, de Mouzon J, Lancaster P, Mansour R, Sullivan E; International Committee Monitoring Assisted Reproductive Technologies. The ICMART glossary on ART terminology. Hum Reprod. 2006 Aug;21(8):1968-70. doi: 10.1093/humrep/del171. Epub 2006 Jul 24.

Reference Type BACKGROUND
PMID: 16864610 (View on PubMed)

Zhang Y, Xu Y, Xue Q, Shang J, Yang X, Shan X, Kuai Y, Wang S, Zeng C. Discordance between antral follicle counts and anti-Mullerian hormone levels in women undergoing in vitro fertilization. Reprod Biol Endocrinol. 2019 Jul 4;17(1):51. doi: 10.1186/s12958-019-0497-4.

Reference Type BACKGROUND
PMID: 31272468 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

REFA073

Identifier Type: OTHER

Identifier Source: secondary_id

FCEC-1-21-22-GRD-1-SF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical Trial of Anovulatory Infertility
NCT06601452 ENROLLING_BY_INVITATION EARLY_PHASE1